Trials / Active Not Recruiting
Active Not RecruitingNCT05377684
Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment
Noninterventional, Multicentre, Prospective, Cohort Study Assessing the Quality of Life and Hormonal Levels in Premenopausal Patients With Hormone Receptor-positive and HER2-negative Early Breast Cancer in Italy - ROSE Study
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 450 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the quality of life of premenopausal participants with Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor-2 (HER2) negative breast cancer who are receiving, in addition to triptorelin, an endocrine cancer treatment. The study will also get more information about: - the effectiveness and safety of triptorelin; - the relationship that could exist between the characteristics of the disease and the treatment chosen by the Investigator.
Conditions
Timeline
- Start date
- 2022-06-09
- Primary completion
- 2026-06-05
- Completion
- 2026-06-05
- First posted
- 2022-05-17
- Last updated
- 2026-04-01
Locations
22 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT05377684. Inclusion in this directory is not an endorsement.